Please click on a tab to view each report.
Efficacy of the Violett L Standalone Indoor Air Purifier Against Aerosolized MS2 Bacteriophage
This study was done to test a prototype version of the Violett L for its efficacy at reducing a single microorganism, the bacteriophage MS2, from indoor room air.
This in-vitro study characterized the efficacy of Violett L, indoor air purifier, to reduce respirable bioaerosol levels for a single viral bioaerosol from the air in a 16m3 stainless steel bioaerosol test chamber. The species selected for this study was the virus MS2, a bacteriophage, which is a recognized surrogate for more dangerous pathogenic organisms. MS2 is a non-enveloped ssRNA virus that is a common surrogate for influenza viruses and is a tentative surrogate for SARS-CoV-2.
MS2 bacteriophage was aerosolized into a sealed 16m3 environmental bioaerosol chamber, containing the Violett L, using a Collison 24-Jet Nebulizer. The MS2 bioaerosols had a mass median aerodynamic diameter (MMAD) averaging at 0.7µm (700nm). Bioaerosol samples were taken, with impingers, at multiple time points throughout each trial, in order to quantify the reduction rate capability of the air purification device. The impinger samples were serially diluted, plated, incubated, and enumerated in triplicate to yield viable bioaerosol concentration for each sampling point. Chamber control trial data, or natural decay rate, was subtracted from the device trial data to yield the net log reduction for each of the bioaerosol challenges.
The device achieved an average log reduction of 6.45 +/- 0.28 within 30 minutes. This equates to a netlog reduction of 6.21 +/- 0.28 (> 99.9999%) when accounting for control losses. These results show that the Violett L device is extremely effective at the rapid removal of viral bioaerosols from room air, achieving a 4 net log (99.99%) reduction within eighteen (18) minutes.
In conclusion, the Violett L device achieved >4 net log reduction of MS2 bacteriophage bioaerosols within a short period of time by achieving a 6.21 (99.9999%) net log reduction within thirty (30) minutes. It is anticipated that such a reduction should reduce the likelihood of individuals being exposed to and contracting airborne infectious diseases in any enclosed environment, medical or otherwise.
Efficacy of the Violett M Standalone Indoor Air Purifier Against Aerosolized MS2 Bacteriophage
This study was done to test a prototype version of the Violett M for its efficacy at reducing a single microorganism, the bacteriophage MS2, from indoor room air.
This in-vitro study characterized the efficacy of Violett M, indoor air purifier, to reduce respirable bioaerosol levels for a single viral bioaerosol from the air in a 16m3 stainless steel bioaerosol test chamber. The species selected for this study was the virus MS2, a bacteriophage, which is a recognized surrogate for more dangerous pathogenic organisms. MS2 is a non-enveloped ssRNA virus that is a common surrogate for influenza viruses and is a tentative surrogate for SARS-CoV-2.
MS2 bacteriophage was aerosolized into a sealed 16m3 environmental bioaerosol chamber, containing the Violett M, using a Collison 24-Jet Nebulizer. The MS2 bioaerosols had a mass median aerodynamic diameter (MMAD) averaging at 0.7µm (700nm). Bioaerosol samples were taken, with impingers, at multiple time points throughout each trial, to quantify the reduction rate capability of the air purification device over time. The impinger samples were serially diluted, plated, incubated, and enumerated in triplicate to yield viable bioaerosol concentrations for each of the sampling timepoints. Chamber control trial data, or the natural loss rate, was subtracted from the device trial data to yield the net log reduction for each of the bioaerosol challenges.
The device achieved an average log reduction of -6.77 +/- 0.09 in 60 minutes. This equates to a net log reduction of 6.42 +/- 0.09 (> 99.999961%) when accounting for control losses. These results show that the Violett M device is extremely effective at the rapid removal of viral bioaerosols from room air, achieving a 4-net log (99.99%) reduction within thirty-five (35) minutes.
In conclusion, the Violett M device achieved >4 net log reduction of MS2 bacteriophage bioaerosols within about thirty-five minutes and a 6.42 net log (>99.9999%) reduction within sixty (60) minutes of operation. It is anticipated that such a reduction should reduce the likelihood of individuals being exposed to and contracting airborne infectious diseases in any enclosed environment, medical or otherwise.
Evaluating Efficacy of Violett Device to Sterilize Virus-Laden Air and Prevent SARS-CoV-2 Transmission
An independent U.S. university with a reputable infectious disease department tested the efficacy of the Violett device and demonstrated the prevention of airborne transmission of the Covid-19 virus SARS-CoV-2 in a hamster model. Our test system had air from a cage with SARS-CoV-2 infected and shedding hamsters flowing into two peripheral cages, each of which contained uninfected (naïve) hamsters. The air on each side flowed through a Violett device. The device on one side (left side below) was turned on such that air flowing through it was sterilized, and the device on the other side did not have UV light on (right side below).

In each replicate, three hamsters were infected intranasally with 104pfu SARS-CoV-2 virus (Wuhan strain) under sedation and co-housed in the central cage for 1 day. Next, with the device continuously running, 3 naïve hamsters were introduced into each of the two peripheral cages (total of 6 hamsters). The device remained on for a total of 48 hours during the peak viral shedding of the infected hamsters in the central cage. At the completion of the exposure period, the hamsters in the peripheral cages were immediately moved to clean cages and maintained for 3 days to evaluate if the hamsters became infected.
Our results demonstrate that the Violett device completely protects against transmission of SARS-CoV-2 in a hamster model. No infectious virus was detected in the upper respiratory or lower respiratory tract from the Violett-treated hamsters while the control hamsters did have replicating virus (Figure A).
*Results representative of 2 independent replicates with additional studies ongoing.